MapLight Therapeutics aims to raise around $251m via an initial public offering (IPO), a figure that would propel the biotech to the upper echelons of the sector’s public listing value so far in 2025. Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech will trade on the Nasdaq Global Market under the symbol "MPLT." In terms of timings, MapLight has used a regu ...

MapLight的核心研发管线集中在治疗精神分裂症和阿尔茨海默病精神病(ADP)领域。其主要候选药物 ML-007C-MA是一种固定剂量组合疗法，结合了M1/M4胆碱能受体激动剂与外周抗胆碱药物，用于改善 认知与精神症状。目前公司正在进行两项二期临床试验：一项针对精神分裂症患者，预计在2026年下半 年公布主要结果；另一项针对ADP的研究预计将在2027年下半年公布关键数据。 MapLight成立于2018年，计划在纳斯达克挂牌上市，股票代码为"MPLT"。摩根士丹利、杰富瑞、 Leerink Partners和Stifel担任此次发行的联合承销商，公司预计将在2025年10月27日当周完成定价。 分析人士指出，在美国政府关门的特殊背景下，MapLight成为少数选择依据"8(a)"法条上市的企业之 一，此举不仅体现出其加速登陆资本市场的决心，也可能成为未来生物医药公司在行政停摆情况下的潜 在参考案例。 智通财经APP获悉，总部位于美国加州红木城的生物技术公司MapLight Therapeutics周一公布首次公开 募股(IPO)条款，计划通过发行1480万股普通股，以每股17美元的价格募集约2.51亿美元 ...

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initi ...